- |||||||||| methimazole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Journal: De Novo Graves' Disease in a 10-Year-Old Girl Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Idiopathic Central Precocious Puberty: A Case Report. (Pubmed Central) - Jul 3, 2025
The patient presented with headache and vomiting during leuprorelin acetate treatment...Subsequently, GnRH agonist therapy was discontinued, and thiamazole treatment resulted in normalized thyroid function...Current evidence suggests that GnRH agonists precipitate autoimmune thyroid disorders predominantly through two pathways: (i) a sustained hypoestrogenism-driven immune rebound state and (ii) direct GnRH-mediated lymphocyte activation. These mechanisms, combined with our patient's family history, highlight the potential importance of thyroid function monitoring in children receiving long-term GnRH agonist therapy, particularly those with a similar genetic predisposition.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Microfluidic Regulation of Core-Shell PLGA Microspheres for Sustained Release of Leuprolide Acetate. (Pubmed Central) - Jul 3, 2025
Briefly, LA-PLGA-MS could be successfully prepared and regulated using microfluidics and sustained LA release as monodispersed microsphere formulations. The developed technological strategy could provide a precise strategy and experimental reference for applications in delivery systems for water-soluble peptides and proteins.
- |||||||||| Clinical, Review, Journal: Interventions for fertility preservation in women with cancer undergoing chemotherapy. (Pubmed Central) - Jun 19, 2025
Evidence for other outcomes is of low or very low certainty. We are not able to reach any conclusions concerning the choice of controlled ovarian hyperstimulation versus ovarian suppression because there are no data available comparing these fertility preservation interventions.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: The US Supreme Court Joins the Debate Over Gender Dysphoria. (Pubmed Central) - Jun 16, 2025
Treatment involves gonadotropin-releasing hormone agonists, such as leuprolide or histrelin, which are approved by the Food and Drug Administration for use in children with central precocious puberty and are commonly prescribed off-label for adolescents...Certainty about the time available for a youth to consider their gender identity, with the guidance of a professional support team, minimizes the risk of disruptive anxiety that's associated with near-term onset of sexual maturation involving development of irreversible secondary sex characteristics. This Commentary presents the legal arguments in the case and discusses relevant medical literature on this important issue in anticipation of the US Supreme Court's decision on the Tennessee law.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Therapy: A Rare and Life-Threatening Complication. (Pubmed Central) - Jun 5, 2025
We present the case of a 59-year-old male with a history of type 2 diabetes mellitus, hypertension, hyperlipidemia, and prostate cancer who developed intractable headache, nausea, vomiting, photophobia, and blurred vision shortly after receiving a leuprolide, GnRH agonist injection, for the treatment of prostate cancer...Clinicians should maintain a high index of suspicion for pituitary apoplexy in patients presenting with acute neurological or endocrine symptoms following GnRH agonist therapy. Increased awareness and vigilance in at-risk populations are essential, as routine pre-screening for pituitary adenomas is not currently standard practice.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
GnRHa 45 mg SC LA Positively Impacts Predicted Adult Height Depending on the Degree of Bone Age Advancement (ENDOExpo: Poster Area) - Jun 5, 2025 - Abstract #ENDO2025ENDO_3432;
Unanswered questions remain about the benefits regarding height enhancement of starting GnRHa treatment at chronological age (CA) 12 years.Aims: To perform secondary analyses of impact on predicted adult height (PAH) depending on the degree of BA advancement using data from the pivotal trial of the first small-volume, long-acting, subcutaneously administered leuprolide acetate for CPP. 62 children (60 girls) with treatment-na
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Phase classification, Trial completion date: REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov) - Jun 3, 2025
P2, N=94, Active, not recruiting,
Since IM LA and triptorelin have demonstrated usefulness that is comparable to that of traditional GnRH stimulation testing for monitoring CPP, we presume that SC LA may be similarly employed. Phase classification: P4 --> P2 | Trial completion date: Mar 2025 --> Jun 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial completion, Trial completion date, Trial primary completion date: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jun 2, 2025
P2, N=23, Completed,
Phase classification: P4 --> P2 | Trial completion date: Mar 2025 --> Jun 2025 Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: Aug 2025 --> Mar 2025
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Enhancing Pregnancy Outcomes in Women with Adenomyosis: The Role of Gonadotropin Releasing Hormone Agonist (GnRHa) prior to Frozen-thawed Embryo Transfer (Pyrmont Theatre) - May 30, 2025 - Abstract #WCE2025WCE_498;
Participants were categorized into two groups: one receiving a single 3.75 mg dose of depot leuprorelin during the early follicular phase before FET initiation (n=124), and the other without this pretreatment (n=38)...Conclusion Pituitary suppression using depot GnRHa prior to FET significantly increases the pregnancy rate in women with adenomyosis, while demonstrating comparable neonatal outcomes to conventional FET cycles. Further randomized controlled trials are essential to validate the effectiveness of GnRHa and determine the optimal FET protocol for women with adenomyosis diseases.
- |||||||||| IMPACT OF CROSS-HORMONE THERAPY ON BONE MINERAL DENSITY IN TRANS WOMEN: AN UPDATED META-ANALYSIS () - May 28, 2025 - Abstract #EULAR2025EULAR_3558;
Cross-hormone therapy in trans women is associated with modest but significant improvements in bone mineral density at the lumbar spine over 12 months, while maintaining stable BMD at the femoral neck and total femur. These findings underscore the safety of CHT in preserving and potentially enhancing bone health in trans women during the first year of treatment.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date, Real-world evidence, Compliance: RWE About QOL and Compliance of Patients With OFS in China (clinicaltrials.gov) - May 27, 2025
P=N/A, N=562, Completed,
These findings underscore the safety of CHT in preserving and potentially enhancing bone health in trans women during the first year of treatment. Not yet recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Nov 2024
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) - May 23, 2025
P2, N=88, Recruiting,
Not yet recruiting --> Completed | Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Nov 2024 Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Trial primary completion date: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty (clinicaltrials.gov) - May 16, 2025
P4, N=80, Completed,
The quality of life outcomes were favorable with early and adequate GnRH therapy. Recruiting --> Completed | Trial primary completion date: May 2025 --> Dec 2024
- |||||||||| Visanne (dienogest) / Mochida, Bayer, Orilissa (elagolix) / AbbVie
Retrospective data, Journal: Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis. (Pubmed Central) - May 15, 2025
These findings enhance our understanding of the relative efficacy of treatment strategies for pain associated with endometriosis. Future research should focus on conducting larger-scale and rigorously designed clinical trials within the target patient populations to further validate these results.
- |||||||||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Retrospective data, Journal: Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study. (Pubmed Central) - May 13, 2025
Goserelin acetate was found to have good pregnancy outcomes in IVF/ICSI-ET with small amount and shout using days of gonadotropin, but there is a lack of statistical significance when compared to the pregnancy outcomes of triptorelin acetate and leuprorelin. The findings need future confirmation in larger trials or meta-analyses.
- |||||||||| progesterone / Generic mfg.
Progesterone Hypersensitivity Manifesting as Cyclical Urticaria (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_2485;
A leuprolide-induced progesterone suppression test, a diagnostic procedure involving leuprolide administration to suppress endogenous progesterone production, was performed instead. Progesterone hypersensitivity should be considered in the differential diagnosis of cyclical urticaria/allergic reactions, especially if they are noticed to occur in the luteal phase of the menstrual cycle.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
GnRH Agonist Therapy Induced Pituitary Apoplexy (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_2449;
The latency between treatment and symptoms onset is variable. The proposed pathophysiologic mechanism involves pituitary stimulation by GnRH agonists, potentially leading to the underlying adenoma's growth and subsequent tissue infraction or hemorrhage.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Contrasting Clinical Presentations of Pediatric Leydig Cell Tumors: Two Cases with Unique Features (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1256;
A Lupron stimulation test was performed with a non-pubertal peak LH of 4.9 IU/L (< 5 IU/L)...The first case demonstrates the classic presentation with peripheral precocious puberty, whereas the second case highlights progression to central precocious puberty, which complicated the diagnostic process. More studies are needed to determine baseline characteristics of Leydig tumors and risk factors for progression to central precocious puberty.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Effectiveness of 6-Month Gnrha Formulations for Pubertal Suppression in Youth Assigned Male-At-Birth (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1217;
More studies are needed to determine baseline characteristics of Leydig tumors and risk factors for progression to central precocious puberty. In addition to monthly and three-monthly formulations, new long-acting GnRHa products, triptorelin and leuprolide acetate (Triptodur
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Pubertal Suppression for Youth Assigned Female At Birth: Experience With 6-Month Formulations (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1214;
In addition to monthly and three-monthly formulations, new long-acting GnRHa products, triptorelin and leuprolide acetate (Triptodur Within the last decade, new long-acting GnRHa formulations, triptorelin and leuprolide acetate (Triptodur
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Metastatic Prostate Cancer Masquerading as Paget's Disease of Bone: A Case Report (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_712;
It is crucial for physicians, to consider metastatic prostate cancer in the differential diagnosis when encountering bone lesion that could be mistaken for Paget's disease of bone.Biopsy and histological examination are often necessary to distinguish between these conditions definitely. Multidisciplinary care and close coordination among specialties are vital to ensure accurate diagnosis and optimal patient management.
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial primary completion date: PRIME-CUT: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - Apr 25, 2025
P2, N=26, Active, not recruiting,
The potential of LA for the treatment of urinary disorders associated with SCI opens the way to a new therapeutic option for individuals with SCI who would like to have an impact on their daily lives. N=20 --> 26 | Trial primary completion date: Mar 2024 --> Nov 2026
- |||||||||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Use of Epic SlicerDicer to assess pregnancy rates in adolescent and young adult patients with breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6950;
Pregnancies were observed across nearly all therapy groups, highlighting the importance of fertility counseling and family planning discussions for AYA breast cancer patients. This study demonstrates the utility of tools like Epic Slicer Dicer in assessing reproductive outcomes in this unique patient population.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Prognostic relevance of Aurora kinase A (AURKA) expression in prostate cancer (PCa). (Hall A - Posters and Exhibits; Poster Bd #: 260) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1334;
AURKA inhibitors might enhance outcomes of metastatic PCa treated with AR pathway inhibitors by intensifying AR inhibition, increasing DNA-damage-related cell death, and/or preventing escape mechanisms like NEPC. Further studies are needed to identify contexts where AURKA inhibitors can improve metastatic PCa outcomes.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
MAGNIFICATION ENDOSCOPY NARROW-BAND IMAGING ASSISTED TARGETED BIOPSY OF RECTAL ENDOMETRIOSIS (ePoster (online only) - DDW Online Platform) - Apr 17, 2025 - Abstract #DDW2025DDW_8730;
As the patient had not yet developed severe intestinal symptoms, gonadotropin-releasing hormone agonist (leuprorelin) was administered via subcutaneous injection to promote atrophy of the endometriotic tissue and uterine fibroids...EUS-FNA is helpful in arriving at a correct diagnosis, but it is costly and time-consuming. The combined use of ultrasonic endoscopy and magnifying endoscopy can locate the lesion and help improve the detection rate of ectopic endometrial tissue.
|
